CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors
- 24 January 2008
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 57 (8) , 1151-1160
Abstract
Antitumor effects of CD40 ligation appear to involve distinct antitumor effector cells in different experimental models. In this study, we tested whether T cells were required for antitumor effects of agonistic anti-CD40 mAb (αCD40) against immunogenic versus poorly immunogenic tumors. Treatment of mice bearing poorly immunogenic B16 melanoma and its more immunogenic variant, B16-hsp72.1, with αCD40 resulted in a similar level of tumor growth suppression. Depletion of T cells did not reduce the antitumor effects in these 2 tumor models. To generate antitumor T cell responses, C57BL/6 mice were immunized with irradiated B16-hsp72.1. Treatment of these vaccinated mice challenged with a high dose of B16-hsp72.1 tumor cells with αCD40 induced tumor growth suppression, which was reduced by T-cell depletion, demonstrating that T cells were involved in the antitumor effect of αCD40. However, immunized mice depleted of T cells and treated with αCD40 were still able to suppress tumor growth as compared to tumor growth in immunized, T cell-depleted mice not treated with αCD40, suggesting that T cells were not required for the antitumor effect of αCD40. To confirm a lack of correlation between tumor immunogenicity and T-cell requirement in antitumor effects of CD40 ligation, we found that αCD40 induced tumor growth suppression in nude and SCID/beige mice bearing highly immunogenic tumors such as Meth A sarcoma, suggesting that macrophages may play a role. Indeed, both poorly immunogenic and highly immunogenic tumors were sensitive to in vitro growth inhibition by macrophages from αCD40-treated mice. Taken together, our results indicate that antitumor effects induced by αCD40, even against immunogenic tumors, can be observed in the absence of T cells and may involve macrophages.Keywords
This publication has 30 references indexed in Scilit:
- Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal AntibodyJournal of Clinical Oncology, 2007
- Tumoristatic effects of anti‐CD40 mAb‐activated macrophages involve nitric oxide and tumour necrosis factor‐αImmunology, 2006
- In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophagesJournal of Leukocyte Biology, 2006
- Modulation of costimulation to enhance tumor immunityCancer Immunology, Immunotherapy, 2003
- CD40 stimulation leads to effective therapy of CD40−tumors through induction of strong systemic cytotoxic T lymphocyte immunityProceedings of the National Academy of Sciences, 2002
- CD40 stimulation accelerates deletion of tumor-specific CD8+T cells in the absence of tumor-antigen vaccinationProceedings of the National Academy of Sciences, 2001
- The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class SwitchingImmunity, 1996
- Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.Journal of Experimental Medicine, 1984
- T-cell function and specificity in athymic miceImmunology Today, 1983
- Immunosuppressive Consequences of Radiotherapy and Chemotherapy in Patients with Acute Lymphoblastic LeukaemiaBMJ, 1973